An interesting approach for ocular diseases: intravitreal administration of RNAi for gene silencing. As all things - rather depends on the target gene and target cells.

Bausch + Lomb pens $485M-plus biobucks pact with City Tx for RNAi eye disease work

Comments

Posting Rules

  • Be respectful to others
  • No spam or self-promotion
  • Stay on topic
  • Follow Bluesky's terms of service